Intelligence · Clinical Pipeline
Biogen Pipeline
All ClinicalTrials.gov programs at Biogen — phase, modality, and trial IDs.
- Programs
- 4
Quick answer
Biogen has 4 clinical development programs indexed from ClinicalTrials.gov, including phase, modality, indication text, and linked NCT identifiers.
-
Felzartamab
Biogen
Immunoglobulin A (IgA) Nephropathy
1 trial -
Felzartamab, Saline Solution Basi 9 mg/ml solution for infusion
Biogen
Treatment of Late Isolated Microvascular Inflammation in Recipients of Kidney Transplants
1 trial -
Matching Placebo tablets without active substance, BIIB122
Biogen
Parkinson's Disease
1 trial -
X-vivo 15 (serum-free growth medium manufactured under gmp and commercially available from Lonza)
Biogen
Peripherial arterial disease (PAD) & Chronic-Limb Threatening Ischemia (CLTI) patients who have not responded to standard pharmacological treatment or control of risk factors, and/or had a revascularisation with continued presence of smaller vessel (microvasculature) disease, and do not have the option of a revascularization treatment.
1 trial
Frequently asked questions
How many pipeline programs does Biogen have?
4 published programs are linked to this sponsor in our ClinicalTrials.gov index.
Is this the complete company pipeline?
This hub lists all published programs for the sponsor in our database. Partnered or out-licensed assets may appear under multiple companies.
Data attribution: Data sources · All pipeline programs